Eur J Endocrinol
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

DOI: 10.1530/eje.1.02145
European Journal of Endocrinology, Vol 154, Issue 5, 723-730
Copyright © 2006 by European Society of Endocrinology
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via Web of Science (3)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Fernández-Real, J. M.
Right arrow Articles by Ricart, W.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Fernández-Real, J. M.
Right arrow Articles by Ricart, W.
CLINICAL STUDY

An alternative spliced variant of circulating soluble tumor necrosis factor-{alpha} receptor-2 is paradoxically associated with insulin action

José Manuel Fernández-Real, Marek Straczkowski1, Begoña Lainez, Matilde R Chacón2, Irina Kowalska1, Abel López-Bermejo, Antonio García-España2, Agnieszka Nikolajuk1, Ida Kinalska1 and Wifredo Ricart

Section of Diabetes, Endocrinology and Nutrition, University Hospital of Girona ‘Dr. Josep Trueta’, Ctra. França s/n, 17007 Girona, Spain, 1 Department of Endocrinology, Diabetology and Internal Medicine, Medical Academy, Bialystok, Poland and 2 Endocrinology and Research Unit, Hospital Universitari Joan XXIII from Tarragona, Rovira i Virgili University, Spain

(Correspondence should be addressed to J M Fernández-Real; Email: uden.jmfernandezreal{at}htrueta.scs.es)

Objective: Serum concentrations of soluble tumor necrosis factor-{alpha} (TNF-{alpha}) receptor 2 (sTNFR2) are associated with insulin resistance. In a recent study, we provided evidence for the existence of a biologically active form of sTNFR2 produced by alternative splicing (DS-TNFR2). We aimed to evaluate whether this circulating DS-TNFR2 is associated with insulin action in humans.

Design and methods: Real time PCR (light cycler technology) evaluated DS-TNFR2 expression in monocytes. DS-TNFR2 was measured using a monoclonal antibody against an epitope present in TNFR2 (first 14 residues of the juxtamembrane region) but predicted to be absent in soluble proteolytic cleavage-produced TNFR2. Insulin sensitivity was measured using euglycemic hyperinsulinemic clamp (n = 76) and homeostatic model of assessment (HOMA) value in a replication study of 223 subjects.

Results: Real time PCR confirmed gene expression of DS-TNFR2 in monocytes from healthy subjects. A significant and positive association was found between serum DS-TNFR2 concentration and insulin sensitivity (P = 0.032, n = 76). This association was most significant in subjects with normal glucose tolerance (r = 0.44, P = 0.002). The subjects in whom DS-TNFR2 was detectable were more insulin sensitive than those with undetectable DS-TNFR2 (42.12±22.08 vs 31.71± 16.95 µmol x kg–1 x min–1, P = 0.039). DS-TNFR2 was inversely associated with body mass index, waist-to-hip ratio, systolic and diastolic blood pressure, fasting serum glucose, serum triglycerides and serum uric acid concentration and with the HOMA value (P = 0.03) in the replication study. Circulating DS-TNFR2 declined with increased number of components of the metabolic syndrome.

Conclusion: Native sTNFR2 and DS-TNFR2 show opposite associations with insulin action. DS-TNFR2 might play a role as a counterpart of the proinflammatory environment associated with insulin resistance.






HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2006 European Society of Endocrinology.